Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.
about
Mitral valve repair versus replacementNoncoding RNA in age-related cardiovascular diseasesMitral-valve repair versus replacement for severe ischemic mitral regurgitation.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunctionLeft Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial.The importance of left ventricular function for long-term outcome after primary percutaneous coronary intervention.Agreement of left ventricular mass in steady state free precession and delayed enhancement MR images: implications for quantification of fibrosis in congenital and ischemic heart diseaseCilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study.Factors likely to affect the long-term results of ventricular stimulation after myocardial infarctionMacrophage roles following myocardial infarctionLong-term influence of mild or moderate ischemic mitral regurgitation after off-pump coronary artery bypass surgery.The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure.Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.The role of inflammatory and fibrogenic pathways in heart failure associated with aging.Endothelial function as a therapeutic target in coronary artery disease.Measurement of the renin-angiotensin system in heart failure.Infarct restraint to limit adverse ventricular remodeling.Usefulness of the Echocardiographic Multi-Parameter Score (EMPS) in evaluating left ventricular global heart function.Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction.Senescent cardiac fibroblast is critical for cardiac fibrosis after myocardial infarction.Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction.The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigsAngiogenesis, cardiomyocyte proliferation and anti-fibrotic effects underlie structural preservation post-infarction by intramyocardially-injected cardiospheres.Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival.Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses.A novel method for quantifying the in-vivo mechanical effect of material injected into a myocardial infarction.Effect of Ginkgo biloba extract on experimental cardiac remodeling.Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction.Comparison of Baseline versus Posttreatment Left Ventricular Ejection Fraction in Patients with Acute Decompensated Heart Failure for Predicting Cardiovascular Outcome: Implications from Single-Center Systolic Heart Failure Cohort.Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or redundant?Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarctionRemote ischaemic postconditioning protects the heart during acute myocardial infarction in pigsVentricular arrhythmias: antiadrenergic therapy for the patient with coronary artery disease.An in vitro model for the assessment of stem cell fate following implantation within the infarct microenvironment identifies ISL-1 expression as the strongest predictor of c-Kit(+) cardiac progenitor cells' therapeutic potential.Thin filament remodeling in failing myocardium.Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction.Matrix metalloproteinases as input and output signals for post-myocardial infarction remodelingImaging stem cells implanted in infarcted myocardium.
P2860
Q26796736-E08A1067-8195-4A24-B070-55D64EDC4083Q28081466-A3C744D5-5DC8-47C7-A043-11428C3D80FBQ30411350-3B15E1C8-C25F-4420-AACF-1EAFF3A64731Q30446453-2221BAE2-63EF-4673-9821-2E24AFADA0FAQ31111202-BC4903B4-3711-429F-B7D4-30D54C5C7AEFQ33320899-B72DF6D4-129C-4E59-8D6A-8B9C1958383EQ33526075-41E2C98A-FC28-4C21-BA9B-13660490F8C6Q33739040-1234381E-D365-4EAD-8EE6-EC257B2F3A04Q33762960-D2D172A8-A450-4653-B4E1-A5444A792085Q33802153-D45FB3FF-999A-41C7-A523-21C1B41D5058Q33916631-BB333101-0A58-4EBE-BDD4-8DC6B3BEADB0Q34027423-76CC0B8E-0EB6-4E0A-B998-5444C0CDFEE4Q34027512-8AA24E6E-D400-4AB7-80C1-DA4764500D46Q34061245-355E4AEA-1C29-405C-B87E-D574E0345D82Q34107475-71C092F7-29B7-4E20-A298-F200FC0835E2Q34170513-6DE188D2-1010-4583-B344-F09D23BA1DECQ34491735-E783DA4F-690D-462C-9AE0-0CEA6FBB7F3CQ34698004-E3F7823D-D659-4040-AA93-CA948AFAF994Q34963719-EBAA671C-4ACE-446D-90C8-2D010BAED345Q34990106-E18B31A1-2E86-4F4D-A449-C5D0002C6555Q35037360-6BFEBE14-FE51-4DD3-A21C-CB9526D05AA6Q35085312-30FE784A-8D32-44EE-8A46-2D5059C12865Q35099604-721AA16D-8985-485D-A2CA-EB3810642143Q35102931-5953782C-188E-402B-87E4-F213DE8349E9Q35136114-DC9543F1-B3FB-41FE-8C20-6F562C3F8233Q35250109-E25D879A-39F4-4B64-B8F6-E26E365FF77EQ35744419-BE938C42-166F-47F1-8653-7E6B672788B3Q35808270-B28ADB56-5D9D-49DF-BD44-F7667117D9C5Q35890556-E7F035B9-AE03-4186-919D-B26467B4B6BAQ35900886-845468B1-579C-4004-A918-BDF2F029F771Q35947836-1EBAB00B-570F-439D-A3C9-58BB83A527AAQ35954778-ED98CA81-0EF8-440F-A457-2CFBF859B0D9Q36167677-19A8BF3A-DEDC-455D-B224-6ACDF5A8851EQ36269172-699F7A6C-D9F0-4443-9F57-95B5C961C5BEQ36369914-20683477-35B3-4806-9266-00A18D45CD9CQ36370540-2BB17631-8094-47E1-B2B2-ADDDF1E338EFQ36383779-20A48AAE-DCDB-4018-9B54-6473F9452C0BQ36531143-3F5C3B84-8A55-421F-8221-302C48DACE39Q36609629-89C6F62A-11D7-4849-A221-B4E1C6B7D017Q36656791-15AB493E-E1EC-4DBD-91A6-66685A15BBC9
P2860
Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@ast
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@en
Cardiovascular death and left ...... al and Ventricular Enlargement
@nl
type
label
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@ast
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@en
Cardiovascular death and left ...... al and Ventricular Enlargement
@nl
prefLabel
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@ast
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@en
Cardiovascular death and left ...... al and Ventricular Enlargement
@nl
P2093
P1433
P1476
Cardiovascular death and left ...... ular Enlargement (SAVE) trial.
@en
P2093
Braunwald E
Pfeffer MA
Plappert T
Rouleau JL
St John Sutton M
P304
P356
10.1161/01.CIR.96.10.3294
P407
P577
1997-11-01T00:00:00Z